EQ - Equillium Inc

0.4727
0.004   0.783%

Share volume: 171,276
Last Updated: 04-04-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.02%

PREVIOUS CLOSE
CHG
CHG%
$0.47
0.00
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
27%
Profitability 0%
Dept financing 15%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.73%
1 Month
-40.62%
3 Months
-38.21%
6 Months
-38.21%
1 Year
-38.21%
2 Year
-38.21%
Key data
Stock price
$0.47
P/E Ratio 
0.00
DAY RANGE
$0.43 - $0.53
EPS 
-$0.16
52 WEEK RANGE
$0.36 - $0.87
52 WEEK CHANGE
-$38.21
MARKET CAP 
26.509 M
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$202,778
AVERAGE 30 VOLUME 
$158,583
Company detail
CEO: Bruce D. Steel
Region: US
Website: equilliumbio.com
Employees: 40
IPO year: 2018
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Equillium, Inc. develops and sells products to treat severe autoimmune and inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6.

Recent news
loading